Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.011.0%$662.14m
AMGNAmgen Inc.
0.57%154.670.8%$509.58m
CELGCelgene Corporation
-0.85%112.661.0%$466.03m
ARIAARIAD Pharmaceuticals, Inc.
0.21%23.7516.4%$442.07m
BIIBBiogen Inc.
0.11%280.661.0%$398.14m
REGNRegeneron Pharmaceuticals, Inc.
-0.23%362.562.5%$365.69m
ALXNAlexion Pharmaceuticals, Inc.
-1.77%131.972.5%$347.73m
ILMNIllumina, Inc.
-0.52%159.743.8%$229.47m
CLVSClovis Oncology, Inc.
2.07%58.2917.9%$160.24m
INCYIncyte Corporation
-0.26%117.222.2%$158.22m
VRTXVertex Pharmaceuticals Incorporated
0.57%81.372.1%$144.14m
TSROTESARO, Inc.
-1.94%147.0015.0%$106.77m
IONSIonis Pharmaceuticals, Inc.
0.58%46.978.9%$101.63m
SRPTSarepta Therapeutics, Inc.
-4.59%32.6616.8%$101.57m
BMRNBioMarin Pharmaceutical Inc.
-1.78%84.624.9%$95.71m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.